Electronic Publication of Patents Journal under The Patents (Amendments) Act, 2016

Weekending:- 04-01-2019

Legal Publication Date:- 23-01-2019

Journal Code (190123)

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

03-01-2019		
1/2019	Iqra University Karachi – Pakistan	"LOST; The Threat is Everywhere"
2/2019	Ghulam Muhammad Sami Ullah Asif Muzaffar Garh - Pakistan	"Engine Based Racking Machine for poultry sheds"
04-01-2019		
3/2019	Hafiz Muhammad Saleem Iqbal Lahore – Pakistan	"A novel processing method for thermal insulation of cylindrical tanks using polystyrene sheets"
4/2019	Ghulam Farooq Kalat – Pakistan	"SHOP TRACKER"

APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Patents' journal may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be as certained on application to the office.

1400/2007	Bayer Intellectual Property GmbH, Germany	**"**NOVEL 2,3-DIHYDROIMIDAZO [1,2-C] QUINAZOLINE COMPOUND**"** A01N43/54 & A61K31/517. **142997** This invention relates to novel 2,3 - dihydroimidazo[1 ,2-c]quinazoline compound having the formula  wherein R^1 is $-(CH_2)_n-(CHR^4)-(CH_2)_m-N(R^5)(R^{5'})$; R^2 is a heteroaryl optionally substituted with 1, 2 or 3 R^6 groups; R^3 is alkyl or cycloalkyl; and the use of those compound and composition for

		phosphatidylinositol-3-kinase (PI3K) inhibition and treating diseases associated with phosphatidylinositol-3-kinase (PI3K) activity, in particular treating hyper-proliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients.
35/2011	SANOFI-AVENTIS France.	"PHARMACEUTICAL COMPOSITION COMPRISING FIBROBLAST GROWTH FACTOR 21 (FGF-21) COMPOUND AND GLUCAGON-LIKE PEPTIDE-1 RECEPTOR (GLP-1 R)" A61K38/18, A61K38/26 & A61P3/00. **142998** The invention is directed to a pharmaceutical composition containing at least one FGF-21 (fibroblast growth factor 21) compound, at least one GLP-1R (glucagon-like peptide-1 receptor) agonist and optionally at least one anti-diabetic drug and/or at least one DPP-4 (dipeptidyl peptidase-4) inhibitor for the treatment of at least one metabolic syndrome and/or atherosclerosis, in particular diabetes, dyslipidemia, obesity and/or adipositas.
264/2012	Galapagos NV, Belgium	"N-4-PHENYLPYRAZOLO [1,5-A] PYRIDIN-2-YL) ACETAMIDE USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES" A61K31/4162, A61P19/02 & C07D471/04. **142999**

		 The novel pyrrazolopyridines according to Formula I, able to inhibit JAK is disclosed, these compound may be prepared as a pharmaceutical composition, and may be used for the prophylaxis and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, allergy, inflammatory conditions, autoimmune diseases, proliferative diseases, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6.
373/2012	Regeneron Pharmaceuticals, Inc. USA	"AN ISOLATED HUMAN ANTIBODY TO HUMAN ANGIOPOIETIN-LIKE PROTEIN 3" A61K39/395 & C07K16/22. **143000** A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits or interferes with at least one activity of human angiopoietin-like protein 3 (hANGPTL3) is provided. The human anti-hANGPTL3 antibodies are useful in treating diseases or disorders associated with ANGPTL3, such as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, hypercholesterolemia, chylomicronemia, and so forth. Furthermore, the anti-hANGPTL3 antibodies can be administered to a subject in need thereof to prevent or treat diseases or disorders, for which abnormal lipid metabolism is

		a risk factor. Such diseases or disorders include cardiovascular diseases, such as atherosclerosis and coronary artery diseases; acute pancreatitis; nonalcoholic steatohepatitis (NASH); diabetes; obesity; and the like.
286/2013	AMMONIA CASALE SA, Switzerland.	"METHOD OF REVAMPING OF AN AMMONIA PLANT FED WITH NATURAL GAS" C01B3/02. **143001** A method of revamping of an ammonia plant fed with natural gas comprising a primary reformer (11) and a secondary reformer (12), the method comprising at least the following interventions: reducing the outlet temperature of the gas (17) flowing out from said primary reformer; adding a feeding line of substantially pure oxygen (30) directed to said secondary reformer (12) to at least partially replace the comburent process air; adding a nitrogen injection line (31) in an amount necessary to obtain a make-up gas suitable for ammonia synthesis. 
339/2013	Phenex Pharmaceuticals AG Germany	"Carboxamide or sulfonamide substituted thiazole and related compound as modulator for the orphan nuclear receptor ROR[gamma]" A61K31/427, A61P17/06, A61P19/02, A61P3/10, C07D 239/28, C07D263/34, C07D277/56, C07D333/38, C07D413/12,

		C07D417/04, C07D417/14, C07D493/08, C07D493/10 & C07D495/10. **143002** The invention provides modulators for the orphan nuclear receptor ROR[gamma] and methods for treating ROR[gamma] mediated diseases by administering these novel ROR[gamma] modulators to a human or a mammal in need thereof. Specifically, the present invention provides carboxamide or sulfonamide containing cyclic compound of Formula (200) and Formula (200')  (200)  (200') wherein R^{201} and R^{202} are independently selected from H, C_{1-10}-alkyl, C_{2-10}-alkenyl, C_{2-10}-alkynyl, C_{3-10}-cycloalkyl, C_{3-10}-heterocycloalkyl, C_{1-10}-alkylene-C_{3-10}-cycloalkyl, C_{1-10}-alkylene-C_{3-10}-heterocycloalkyl, C_{1-10}-alkylene-(5-membered heteroaryl), C_{1-10}-alkylene-(6-membered aryl), C_{1-10}-alkylene-(6-membered heteroaryl), SO_2-C_{1-10}-alkyl, wherein alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is unsubstituted or substituted with 1 to 7 substituents independently selected from the group consisting of oxo, CN, OR^{211}, O-C_{2-6}-alkylene-OR^{211}, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, halogen, CO_2R^{211}, $CONR^{211}R^{212}$, $CONR^{211}SO_2R^{211}$, COR^{211}, SO_XR^{211}, SO_3H, $SO_2NR^{211}R^{212}$, $NR^{211}COR^{211}$, $NR^{211}SO_2R^{211}$, NR^{211}-CO-$NR^{211}R^{212}$, NR^{211}-SO_2-$NR^{211}R^{212}$, C_{3-10}-cycloalkyl, O-C_{3-10}-cycloalkyl, C_{3-10}-heterocycloalkyl, O-C_{3-10} heterocycloalkyl and $NR^{211}R^{212}$; or R^{201} and R^{202} when taken together with the nitrogen to which they are attached complete a 3-

		to 8-membered ring containing carbon atoms and optionally containing 1 or 2 heteroatoms selected from O, S or N, wherein the ring is unsubstituted or substituted with 1 to 4 substituents independently selected from the group consisting of halogen, oxo, CN, OR^{211}, SO_XR^{211}, SO_3H, $NR^{211}SO_2R^{211}$, $SO_2NR^{211}R^{212}$, C0-6-alkylene-CO_2R^{211}, $CONR^{211}R^{212}$, $CONR^{211}SO_2R^{211}$, COR^{211}, NR^{211}-CO-R^{211}, NR^{211}-CO-$NR^{211}R^{212}$, NR^{211}-SO_2-$NR^{211}R^{212}$, $NR^{211}R^{212}$, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, hydroxy-C_{1_6}-alkyl, C_{3-8}-cycloalkyl, O-C_{3_8}-cycloalkyl, C_{3-8}-heterocycloalkyl and O-C_{3_8}- heterocycloalkyl, wherein cycloalkyl and heterocycloalkyl are unsubstituted or substituted with 1 to 4 substituents independently selected from the group consisting of halogen, C_{1_3}-alkyl, halo-¬C_{1_3}-alkyl, OH, O-$_{C1\_3}$-alkyl, O-halo-C_{1_3}-alkyl, SO_2-C_{1_3}-alkyl, COON and oxo; R^{203} is selected from C_{1_10}-alkyl, fluoro-C1_10-alkyl, C_{0_6}-alkylene-C_{3_10}-cycloalkyl, C_{0_6}-alkylene-$C_{3\_\ 10}$-heterocycloalkyl, C_{0_6}-alkylene-(6- to 10-membered aryl), and C_{0_6}-alkylene-(5- to 10- membered heteroaryl), wherein alkyl, alkylene, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is unsubstituted or substituted with 1 to 6 substituents independently selected from the group consisting of oxo, halogen, CN, C_{1_6}-alkyl, halo-C_{1_6}-alkyl, C_{3_6}-cycloalkyl, C_{3_6}-heterocycloalkyl, OR^{212}, CO_2R^{212}, $CONR^{212}R^{212}$ and COR^{212}; and wherein optionally one CH_2 unit in alkyl or alkylene can be replaced by O, SO_x, NH or N(C_{1_3}-alkyl);  (200)  (200')

393/2013	UREA CASALE SA, Switzerland	"A process and apparatus for the granulation of a liquid phase, particularly for the granulation of urea" B01J2/04 & C05C9/00. **143003** Process and apparatus for granulation of a liquid phase, wherein a polydispersed flow of droplets of said liquid phase is generated, with descending motion in contact with solidification air along a substantially vertical granulation path, and wherein inside said polydispersed flow, small-sized droplets solidify producing solid particles, and said solid particles grow by collision with other droplets of liquid; in some embodiments the product obtained with this new granulation method can be grown with the conventional method. 
552/2013	Regeneron Pharmaceuticals, Inc. USA	"HUMAN ANTIBODY TO GFR ALPHA 3 AND PHARMACEUTICAL COMPOSITION THEREOF" A61K39/395, A61P29/00 & C07K16/28.

		143004 The present invention provides an isolated monoclonal antibody or an antigen-binding fragment thereof that specifically binds to GFRa3, wherein the antibody is a human monoclonal antibody comprising (a) a heavy chain variable region (HCVR) having an amino acid sequence selected from the group consisting of SEQ ID NO: 2, 18, 34, 50, 66, 82, 98, 114, 130, 146, 162, 178, 194, 210, 226, 242, 258, 274, 290, 306, 322, 338, 354, 381 and 397 and (b) a light chain variable region (LCVR) having an amino acid sequence selected from the group consisting of SEQ ID NOs : 10, 26, 42, 58, 74, 90, 106, 122, 138, 154, 170, 186, 202, 218, 234, 250, 266, 282, 298, 314, 330, 346, 362, 389 and 405. The antibody or antigen binding fragment of present invention is useful in pain/hypersensitivity associated with a wide range of conditions and disorders in which blocking the interaction of GFRa3 with artemin is desired. The antibod of present invention may also be used to inhibit tumor cell growth,proliferation and/or metastasis.
640/2013	BENELLI ARMI S.P.A., Italy.	"A RECOIL DAMPING DEVICE FOR OPTIMUM PERFORMANCE " F41A25/00. **143005** A recoil damping device comprising a casing in which a recoil damping means is inserted: the damping means includes a fixed part, which is integral with the casing, and a movable part able to slide along a substantially axial direction inside the casing: the damping means is made of a material having a certain elastic hysteresis and includes a set of flexible members connecting the fixed part to the movable part; the flexible members have different stiffnesses.

		
39/2014	DOW AGROSCIENCES LLC U.S.A.	"HERBICIDAL COMPOSITION COMPRISING 4-AMINO-3-CHLORO-6-(4-CHLORO-2-FLUORO-3-METHOXYPHENYL)PYRIDINE-2-CARBOXYLIC ACID AND PROPYZAMIDE" A01N 37/18 & A01N43/40. **143006** Herbicidal composition and method of controlling undesirable vegetation using a combination of (a) a compound of formula (I):  (I) and (b) propyzamide provide control of undesirable vegetation, e.g., in winter/spring oilseed rape, winter/spring canola, vegetables, Brassica spp, ornamentals, rice, wheat, triticale, barley, oats, rye, sorghum, corn/maize, sunflower, row crops, pastures, grasslands, rangelands, fallowland, sugarcane, turf, tree and vine orchards, and industrial vegetation management

		and rights-of-way.
745/2014	ELI LILLY AND COMPANY USA.	"Novel Urea Compound 1-isobutyl-3- [2- [4- [3- [4- [[4-methyl-1- [(2R,3R,4S,SS,6R)-3,4,5 trihyd roxy-6-(hydroxymethyl)tetrahydropyran-2-yl]indol-3-yl] methyl]phenoxy] propyl] 4 ,9-diazaspiro [5.5] undecan-9-yl] -2-oxo-ethyl] urea and Pharmaceutical Composition Thereof" A61K31/7042, C07H19/04 & C07H19/06. **143007** The present invention provides a compound 1 - isobutyl-3-[2-[4-[3-[4-[[4-methyl- 1-[(2R,3R,4S,5S ,6R)-3 ,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]indol-3 - yl]methyl]phenoxy]propyl]-4,9-diazaspiro [5 .5]undecan-9-yl]-2-oxo-ethyl]urea having structural formula I:  Formula I The present invention further provides a pharmaceutical composition comprising above said compound with one or more pharmaceutically acceptable carrier. The compound of present invention is inhibitors of sodium-coupled glucose cotransporters (SGLT's) and is suitable for the treatment of diabetes of type 1 and 2.
767/2014	FMC Corporation, USA.	"A COMPOSITION OF ALGINATE AND DIVALENT SALT SOLUTIONS AND METHOD FOR SETT TREATMENT" A01G1/00, A61K31/70, C08J3/075 & C08L5/04. **143008**

		The present invention relates to the method of treating setts comprising (a) applying a coating of an alginate optionally containing one or more crop protection agents selected from the group of insecticides, nematocides and fungicides, and / or one more nutrients to setts, and (b) applying a coating of a divalent metal ion to setts, thereby crosslinking the alginate with the divalent metal ion. The present invention also relates to a composition used in the treatment of setts including sugarcane setts, comprising, (a) alginate salt solution; and (b) a divalent salt solution.
883/2014	1) LES LABORATOIRES SERVIER France and 2) VERNALIS (R&D) LIMITED United Kingdom	"A NOVEL THIENOPYRIMIDINE COMPOUND, A PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITION THEREOF" A61K 31/519, A61P35/00, A61P37/00 & C07D495/04. **143009** The present invention relates to a compound of formula (I):  (I) wherein R_1, R_2, R_3, R_4, R_5, R_6, R_7, R_{12}, X, A and n are as defined in the claims of the specification. The present invention further provides a pharmaceutical composition comprising claimed compound and one or more pharmaceutically acceptable carrier which is therapeutically

		effective in the treatment of cancer.
178/2015	HANMI PHARM. CO., LTD. Republic of Korea.	"AMORPHOUS SOLID DISPERSION COMPRISING TAXANE, TABLET COMPRISING THE SAME, AND METHOD FOR PREPARING THE SAME" A61K31/335, A61K31/337, A61K9/20 & A61K 9/30. **143010** The present invention provides an amorphous solid dispersion comprising a taxane or a pharmaceutically acceptable polymer, and a pharmaceutically acceptable surfactant, which has enhanced solubility. Also provided is a method for preparing the solid dispersion. The present invention also provides a tablet having good solubility, bioavailability and stability, which comprises the amorphous solid dispersion, an intragranular excipient, and an extragranular excipient.
658/2015	Monsanto Technology LLC USA.	"ENGINEERED INSECTICIDAL PROTEINS COMPRISING AN AMINO ACID SEQUENCE EXHIBITING INHIBITORY ACTIVITY AGAINST LEPIDOPTERA" A01H5/00, C07K14/325 & C12N15/82. **143011** The present invention provides an engineered insecticidal protein comprising an amino acid sequence as set forth in any of SEQ ID NO:44, SEQ ID NO: 40, SEQ ID NO: 12, SEQ ID NO:26, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:16, SEQ ID NO: 18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38 or SEQ ID NO:42, wherein the engineered insecticidal protein exhibits inhibitory activity against an insect species of the order Lepidoptera.

		
711/2015	Asghari Bano and Izhar Ahmad Islamabad - Pakistan.	"Novel method for the Biocontrol of Dengue vector" **143012** The present invention deals with the biocontrol of dengue vector. Dengue is a mosquito- borne viral disease transmitted by female mosquitoes mainly of the species Aedes aegypti and, to a lesser extent, A. albopictus. The method involves the eradication/killing of larvae of the mosquito by spraying crude 80% methanolic extract of plant in distilled water in ditches and tyres where the dengue vector Aedes aegypti is found to lay eggs and produce larvae and by killing adult mosquito following the use of plant extracted oil mixed with coconut oil on human skin. The biomosquitocide can be used as crude methanolic extract , n-hexane fraction of 80%methanolic extract and as isolated active compound l-(+)-ascorbic acid 2,6 di- hexadecanoate and hexadecanoic acid extracted from n hexane fraction of 80% methanolic extract of plants T. androssowil and T. baluchistanica. This biomosquitocide has very low LD_{50} and LD_{90}. The LD_{50} and LD_{90} for n hexane fraction of the methanolic extract varied from 0.42 and 6.2 mg/ml for Tamarix baluchisianica whereas for Tamarix androssowii LD_{50} and LD_{90} varied as 0.47 and 4.7 mg/ ml of shoot extract. The n-hexane fraction of 80% aqueous methanolic extract of T. baluchistanica and chloroform fraction of 80% aqueous methanolic extract of T.

		androssowii resulted in 85% killing of larvae 3h after application. The dried plant extracts and its fractions can be stored at 4 ℃ for 2 years. Tamarix baluchistanica and Tamarix androssowii grow wildly and abundantly throughout the year. The commercial grade chloroform is used for the extraction that costs only 160-200 Rs. per liter. While 90% of the solvent is recovered after each extraction process.
98/2016	ELI LILLY AND COMPANY USA	"N-[3-[(4aS,5S,7aS)-2-amino-5-(1,1-difluoroethyl)-4,4a,5,7-tetrahydrofuro [3,4 d][1,3] thiazin-7a-yl]-4-fluoro-phenyl]-5-(1,2,4-triazol-1-yl)pyrazine-2-carboxamide compound and pharmaceutical composition thereof" A61K31/542, A61P25/28 & C07D 513/04. **143013** The present invention provides a compound of Formula II:  Formula II The invention further provides a pharmaceutical composition comprising above compound with one or more pharmaceutically acceptable carriers, diluents, or excipients and a process for preparation of composition. The compound of present invention is therapeutically effective to treat Alzheimer's disease.
253/2016	AstraZeneca AB Sweden	"Novel 5-lipoxygenase activating protein (FLAP) inhibitors" C0 7D231/40

		143014 The present application relates to novel compounds of formula (I)  to their utility in treating and/or preventing clinical conditions including cardiovascular diseases (CVD), to methods for their therapeutic use, to pharmaceutical compositions containing them and to processes for preparing such compounds.
531/2016	TOYO ENGINEERING CORPORATION Japan.	"UREA MANUFACTURING METHOD AND UREA MANUFACTURING APPARATUS" C07C273/04 & C07C275/00. **143015** Method and apparatus that enable the more efficient manufacture of urea are provided. Before unreacted substances are removed from a urea synthesis solution obtained from a stripper, the urea synthesis solution is placed under pressure reduced from the synthesis pressure. Thus, a gas-liquid mixture is obtained. This fluid is heated with a decomposed gas from the stripper using a shell-and-tube heat exchanger, and then introduced into a purification system. In the heating, the gas-liquid mixture is introduced into the shell of the heat exchanger while the decomposed gas is introduced into the tube side of

		the heat exchanger. 
710/2016	CHIESI FARMACEUTICI S.p.A., Italy.	"A PROCESS FOR PREPARING A DRY POWDER FORMULATION COMPRISING AN ANTICHOLINERGIC, A CORTICOSTEROID AND A BETA-ADRENERGIC" A 61K47/12 **143016** The invention relates to a dry powder formulation for inhalation comprising a combination of an anti-cholinergic, a long-acting beta2-adrenoceptor agonist, and a corticosteroid, and to a process for preparation thereof.
827/2016	PFIZER INC., U.S.A.	"SUBSTITUTED 3-AZABICYCLO[3.1.0]HEXANES AS KETOHEXOKINASE INHIBITOR" A61K31/506, A61P25/02, A61P3/06, A61P3/10, C07D401/14, C07D403/04 & C07D403/14. **143017** The present invention concerns of a compound of Formula I

		 (I) wherein Y is N or C-CN; Z is N or CH; X is N or CR^3; provided that at least one of Y, Z, or X is N; R^1 , R^2 , R^4 as described herein. Provided herein are substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitor and pharmaceutical composition containing the same.
249/2017	Amjad Iqbal, Farooq Shah, Zafar Hayat Khan, Badshah Islam, Tariq Shah, Muhammad Hamayun, Anwar Hussain, Ayaz Ahmad, Dr. Attaullah Rashad Qadri. Mardan - Pakistan Yaodong Yang, China	"EFFICIENT, CHEAP & RELIABLE METHOD FOR THE EXTRACTION OF gDNA FROM THE HARD & COMPLEX TISSUES OF PLANT SPECIES" **143018** The invention associates with the extraction of gDNA by an improved method that comprised of following extraction buffer and steps: the buffer comprised of ammonium thiocyanate, guanidine thiocyanate, sodium acetate, phenol, glycerol, DEPC water,ß-¬merceptoethanol and 1M NaOH (to make the buffer pH=8). The process included pulverization of 0.08 g of tissue in liquid nitrogen and 3% of PVP-40. The pulverized tissue was mixed with extraction buffer and incubated for 4 minutes on ice to isolate 9DNA from the matrices. The supernatant collected after centrifugation for 4 minutes was treated with chloroform to remove impurities. Further impurities were removed by treating the supernatant with chloroform/ isoamyl alcohol. After, a 4 minutes of isopropanol treatment has separated the gDNA in the form of a palette from low molecular weight compounds. The RNA impurities were removed by treating the sample with RNAse for 18 minutes to digest RNA. The DNA was finally precipitated with

		isopropanol, washed with ethanol and re-dissolved in DPEC water. The method efficiently isolated the highly intact gDNA with great purity with in 72 minutes.
870/2018	PFIZER INC., U.S.A.	"PHARMACEUTICALLY ACCEPTABLE SALT OF SUBSTITUTED 3-AZABICYCLO[3.1.0]HEXANES AS KETOHEXOKINASE INHIBITOR" A61K31/506, A61P25/02, A61P3/06, A61P3/10, C07D401/14, C07D403/04 & C07D 403/14. **143019** The present invention concerns pharmaceutically acceptable salt of a compound of Formula I  (I) wherein Y is N or C-CN; Z is N or CH; X is N or CR^3; provided that at least one of Y, Z, or X is N; R^1 , R^2, R^4 as described herein. Provided herein are pharmaceutically acceptable salt of substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitor and pharmaceutical composition containing the same.

SEALING FEES DUE-

Notice is hereby given that the Patent may now be sealed on the application referred to below if it is desired that Patent should be sealed a request on the prescribed Form-10 accompanied by the fee of **Rs.4500/-** should be sent to the Controller of Patents and Designs, The Patent Office, Karachi.

Accepted No.	Applicant Name	Application No.
142905	NOVARTIS AG SWITZERLAND	318/2005
142906	Sanofi-Aventis Deutschland GmbH Germany	471/2010
142907	NOVARTIS AG SWITZERLAND	242/2012
142908	NOVARTIS AG SWITZERLAND	811/2013
142909	CHIESI FARMACEUTICI S.p.A., Italy.	830/2013
142910	CHIESI FARMACEUTICI S.p.A., Italy.	831/2013
142911	DOW AGROSCIENCES LLC, USA.	182/2014
142912	CASALE SA, Switzerland	192/2015
142913	LONATI S.P.A., Italy.	786/2015

NEW APPLICATIONS FOR THE INDUSTRIAL DESIGNS

S. No.	Design No.	Title & Class	Applicant
		01/01/2019	
1	19683	Spring Forced Adjustable clamp for Pipes (Class-01)	Dr.Khurram Kamal, Muhammad Haider Raza Zaidi, Ahmed Ali Tahir and Mehdi Hassan
2	19684	soil moister meter (Class-03)	Muhammad Shahzad Younis
3	19685	Smart Dendrometer (Class-03)	Muhammad Shahzad Younis
		02/01/2019	
4	19686	DOOR FACING (Class 3)	Masonite Corporation
5	19687	DOOR FACING (Class 3)	Masonite Corporation
6	19688	DOOR FACING (Class 3)	Masonite Corporation
7	19689	DOOR FACING (Class 3)	Masonite Corporation
8	19690	DOOR FACING (Class 3)	Masonite Corporation
9	19691	DOOR FACING (Class 3)	Masonite Corporation
		03/01/2019	
10	19692	School Timer ST-12SEG (Class-03)	MRS. HUMAIRA ZUBAIR
11	19693	MOBILE PHONE (Class-03)	VIVO MOBILE COMMUNICATION CO., LTD

REGISTRATION OF DESIGNS

The following designs have been registered.

S. No.	Design No.	Title & Class	Applicant
		03/01/2019	
1.	19172	Spice Dispenser(04)	Summer Hassan, Amsal Mumtaz,
2.	19173	SAHL: Tool Bags for Daily Wage Workers(03)	Manal Jamil, Syed Ahmed Jawwad Zaidi,
3.	19273	ICE-IT (Class-01)	Aqsa Ajmal, Muslim and Amsal Mumtaz
4.	19281	Chopping Board (Class-01)	Hina Khush and Khadija Zia
5.	19282	Herb Chopping and Grinding Device (Class-04)	Alieha Batool, and Khadija Zia
6.	19284	Sleeping unit for PTSD patients (Class-01)	Talha Shahzad and Rao Shahzaib Ali Khan
7.	19285	Wee-Vast (Class-01)	Muhammad Huzaifa and Khadija Zia
8.	19286	Twister (Class-01)	Hira Ejaz, and Khadija Zia
9.	19287	Egg Yolk Separator (Class-03)	Cybil Mary Braganza and Khadija Zia
10.	19292	Spinnet Cutter (Class-01)	Batool Fatima and Khadija Zia
11.	19297	Chashni (Class-01)	Sabah Zaman and Amsal Mumtaz

-sd-

(Dr. Muhammad Fayyaz Ahmad)
Controller of Patents
& Registrar of Designs
Ph: 99230591